Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Endosonics(eson) -- Ignore unavailable to you. Want to Upgrade?

To: Scott Tyriver who wrote (151)	7/28/1998 6:31:00 PM
From: Dr. Bob	Read Replies (2) \| Respond to of 205

I am not a cardiologist, but I believe the post you pasted from Yahoo is inaccurate. My father-in-law has had some heart problems, and two caths. I went to his most recent cardiologist visit with him, where the cardiologist mentioned that an IVUS procedure might be helpful at some point. I certainly understand that it is not a routine procedure, but it seems clear to me that it is a piece of the cardiologists' armamentarium. That's anecdotal, but so was the poster's info. What seems clear from the last earnings report is that people ARE buying this product. As for stents, that field is changing every year. The advantage of being with Cordis was that the same rep could sell both products. When someone comes up with a line of stents, IVUS, flow probes, and other diagnostic and therapeutic products that a cardiologist or hospital can feel like they're getting top of the line material from a single supplier, that supplier will gain a significant advantage. It appears to me that is ESON's strategy. They can't get there without a line of stents to market that are excellent quality. Bob